What does the FDA’s approval of leucovorin mean for patients?
The FDA has approved leucovorin for cerebral folate deficiency, a rare genetic condition affecting about 1 in 1 million people. This decision comes amid growing interest in the drug, particularly regarding its potential use in treating autism, although the FDA has stated there is insufficient evidence to support this application.
Leucovorin, also known as folinic acid, is a high-dose B vitamin traditionally used to counteract the side effects of chemotherapy. It has been used to treat folate deficiency since 2009, but fewer than 50 cases of cerebral folate deficiency have been identified worldwide.
The approval was based on a systematic literature review that included case reports and mechanistic data. Cerebral folate deficiency limits the delivery of folate to the brain, affecting critical functions such as thinking, speech, and movement.
Despite the FDA’s caution regarding its use for autism, some parents have reported improvements in their autistic children after using leucovorin. This has led to a surge in prescriptions, with a reported 71% increase following a White House briefing in September.
However, the largest randomized double-blind, placebo-controlled trial testing leucovorin for autism was retracted due to errors, raising concerns about the reliability of the data. An FDA official noted, “We don’t have sufficient data to say that we could establish efficacy for autism more broadly.”
In a related context, it is estimated that 20-50% of children with autism might produce antibodies that block folate transport, which has fueled interest in leucovorin as a potential treatment. Yet, the FDA remains open to interest from companies looking to study leucovorin in the autism population.
Dr. I. David Goldman expressed concern over the situation, stating, “The damage is done, because parents with autistic kids are desperate.” This sentiment reflects the urgency many families feel as they seek effective treatments.
While some reports suggest that 60% of children with folate deficiency and autism could improve their speech with leucovorin, the long-term effects of the drug on children with autism are not well-documented. Details remain unconfirmed.
As the situation develops, the FDA has not committed to further studies on leucovorin’s efficacy for autism, leaving many questions unanswered for families and healthcare providers alike.